Owen Mumford Unveils New Self-Injection Pen

Owen Mumford, a global industry leader in medical device design and manufacturing, recently unveiled a new addition to its range of medical devices, Ovaleap Pen. The Ovaleap Pen is a re-usable self-injection pen that has been designed for Teva Pharmaceutical Industries Limited for use by it and its affiliates (Teva) to administer Teva’s recently approved fertility treatment. The Ovaleap Pen is CE approved and is Owen Mumford’s first device for the treatment of infertility, in conjunction with Ovaleap.

Ovaleap Pen is designed for ease-of-use, accuracy and flexible dosing, featuring:

-A dial-back feature allowing quick and easy correction if the dose is set incorrectly
-A side-button for injection administration with one simple sliding action, for greater ease of use
-A large dosage window with legible numbers that confirms the dose size as figures

-A clear cartridge holder letting the end-user see how much medication is inside


As Ovaleap Pen is re-usable, this reduces the need to discard left over medication and minimizes pen waste. 


“Ovaleap Pen is derived from our existing, proven Autopen2 platform – an injection pen with dose control, created to overcome some of the barriers end-users face when self-injecting,” said Sian Eden, Account Manager, at Owen Mumford. “Ovaleap Pen has been developed with the end-user in mind, supporting accurate dosage. The pen can hold three different cartridge sizes and end-users can adjust their dose by 6.25-microL increments.

Owen Mumford is passionate about developing products that meet end-user needs and address healthcare issues. Its confident the Ovaleap Pen will be a convenient and patient-friendly device to support patients going through fertility treatment. Fertility being a major challenge as Europe has the lowest fertility rate in the world and in the UK, one in seven couples will experience infertility issues. Ovaleap Pen is now available in several European countries including the United Kingdom. Autopen is a registered trade mark of Owen Mumford Ltd.
Ovaleap Pen is a registered trademark of Teva Pharmaceuticals Europe B.V.

Owen Mumford is a major medical device manufacturer that develops pioneering medical devices for its own Owen Mumford brand and custom device solutions for the world’s major pharmaceutical and diagnostic companies. Owen Mumford’s goal is to improve quality of life, encourage adherence to treatment, and reduce healthcare costs. With a history of world firsts in device solutions, Owen Mumford offers proven design, development, and delivery services from a broad base of proven self-injection and blood sampling platform devices and intellectual property.

In business for over 60 years, Owen Mumford remains privately owned with a focus on long-term investment to deliver sustainable business growth. With a strong internal research and development capability, Owen Mumford’s goal is to develop solutions that address today’s healthcare demands. Through advanced research involving end-users and healthcare professionals, and extensive design and manufacturing capabilities, Owen Mumford produces class-leading medical devices that are used by a global audience – exporting over 85% of its products to more than 60 countries worldwide.
Selected as one of The World Economic Forum’s Global Growth Companies in 2014, Owen Mumford is a trusted partner to many of the world’s biggest medical device diagnostic and pharmaceutical companies and works with international organizations to support customers at a local level and provide consistent and dedicated support.
For more information, visit www.owenmumford.com.